Clinical trial results:
A randomised prospective study assessing changes in neuro-cognitive function, using a computerised test battery, in treatment naïve HIV-1 positive subjects commencing two different antiretroviral regimens.

Summary

EudraCT number	2007-002405-47
Trial protocol	GB
Global end of trial date	01 October 2014

Results information

Result version number	v1 (current)
This version publication date	16 October 2019
First version publication date	16 October 2019

Trial information

Trial identification

Sponsor protocol code	The CogNaive Study

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00540137
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Imperial College London
Sponsor organisation address	South Kensington Campus, London , United Kingdom, SW7 2AZ
Public contact	Prof Alan Winston, Imperial College London, +44 (0)20 3312 1603, a.winston@imperial.ac.uk
Scientific contact	Prof Alan Winston, Imperial College London, +44 (0)20 3312 1603, a.winston@imperial.ac.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 October 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 October 2014
Global end of trial reached?	Yes
Global end of trial date	01 October 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the changes in simple reaction time of study period as measured by a computerised test battery

Protection of trial subjects:

None

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 February 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 20
Worldwide total number of subjects	20
EEA total number of subjects	20

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	20
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participant were recruited at Imperial College Healthcare NHS Trust (St Mary's Hospital, London, UK) and the Heart of England NHS Foundation Trust (Birmingham, UK) between February 2008 and October 2012.

Pre-assignment

Screening details:

24 subjects were screened, 20 were enrolled and 14 completed all study procedures.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

open-labelled

Arms

Are arms mutually exclusive?	Yes
Arm title	Atazanavir

Arm description:

emtricitabine (200 mg once daily) + tenofovir disoproxil fumarate (245 mg once daily)+ atazanavir (300 mg once daily)

Arm type	Experimental
Investigational medicinal product name	Emtricitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

200mg daily

Investigational medicinal product name	Atazanavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

300mg daily

Investigational medicinal product name	Tenofovir disoproxil fumarate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

245 mg once daily

Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details: 100mg daily

Arm title	Nevirapine
Arm description: Participants received emtricitabine (200 mg once daily) + tenofovir disoproxil fumarate (245 mg once daily) plus nevirapine 400 mg (once daily).	
Arm type	Experimental
Investigational medicinal product name	Emtricitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 200mg daily	
Investigational medicinal product name	Tenofovir disoproxil fumarate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 245 mg once daily	
Investigational medicinal product name	Nevirapine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 400 mg once daily	

Number of subjects in period 1	Atazanavir	Nevirapine
Started	10	10
Completed	9	5
Not completed	1	5
Consent withdrawn by subject	1	3
Lack of cognitive data	-	2

Baseline characteristics

Reporting groups	
Reporting group title	Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	20	20	
Age categorical Units: Subjects			
Adults (18-64 years)	20	20	
Age continuous Units: years			
geometric mean	37.4		
full range (min-max)	23 to 48	-	
Gender categorical Units: Subjects			
Female	0	0	
Male	20	20	

End points

End points reporting groups

Reporting group title	Atazanavir
Reporting group description:	
emtricitabine (200 mg once daily) + tenofovir disoproxil fumarate (245 mg once daily)+ atazanavir (300 mg once daily)	
Reporting group title	Nevirapine
Reporting group description:	
Participants received emtricitabine (200 mg once daily) + tenofovir disoproxil fumarate (245 mg once daily) plus nevirapine 400 mg (once daily).	
Subject analysis set title	All participants_24weeks
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Given only 14 subjects completed our study, this analysis is descriptive with no formal comparisons across treatment arms, we merged the two arm from the beginning to one arm. Results on 24weeks	

Subject analysis set title	All participants_48weeks
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Given only 14 subjects completed our study, this analysis is descriptive with no formal comparisons across treatment arms, we merged the two arm from the beginning to one arm. Results on 48weeks	

Primary: Changes in Cognitive Function

End point title	Changes in Cognitive Function
End point description:	
Cognitive scores were transformed using standardised z-scores according to the pooled baseline standard deviation, score increase means better cognitive function	
End point type	Primary
End point timeframe:	
24 weeks, 48 weeks	

End point values	All participants_24 weeks	All participants_48 weeks		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	14	14		
Units: unit on the scale				
geometric mean (standard deviation)	0.08 (± 0.54)	0.15 (± 0.60)		

Statistical analyses

Statistical analysis title	Cognitive Function
Comparison groups	All participants_24weeks v All participants_48weeks

Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.43
Method	t-test, 2-sided

Adverse events

Adverse events information[1]

Timeframe for reporting adverse events:

1 year

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	10

Reporting groups

Reporting group title	Atazanavir

Reporting group description:

emtricitabine (200 mg once daily) + tenofovir disoproxil fumarate (245 mg once daily)+ atazanavir (300 mg once daily)

Reporting group title	Nevirapine

Reporting group description:

Participants received emtricitabine (200 mg once daily) + tenofovir disoproxil fumarate (245 mg once daily) plus nevirapine 400 mg (once daily).

Serious adverse events	Atazanavir	Nevirapine	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Atazanavir	Nevirapine	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 10 (0.00%)	0 / 10 (0.00%)	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: No none serious adverse event on the study.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

http://www.ncbi.nlm.nih.gov/pubmed/27081393